Victory Square Technologies Inc (TSE:VST) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Victory Square Technologies Inc. expands its medical offerings through Hydreight Technologies with the addition of Tirzepatide, enhancing their weight loss portfolio that already includes GLP-1 injections. This move aims to provide cost-effective diabetes and weight loss treatments across the US, leveraging a robust network of over 3,000 nurses and 107 white-label locations. Tirzepatide, an FDA-approved medicine for type 2 diabetes, is recognized for its weight loss benefits and will now be available in over 700 cities nationwide.
For further insights into TSE:VST stock, check out TipRanks’ Stock Analysis page.